BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35641155)

  • 1. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK.
    Shields AM; Anantharachagan A; Arumugakani G; Baker K; Bahal S; Baxendale H; Bermingham W; Bhole M; Boules E; Bright P; Chopra C; Cliffe L; Cleave B; Dempster J; Devlin L; Dhalla F; Diwakar L; Drewe E; Duncan C; Dziadzio M; Elcombe S; Elkhalifa S; Gennery A; Ghanta H; Goddard S; Grigoriadou S; Hackett S; Hayman G; Herriot R; Herwadkar A; Huissoon A; Jain R; Jolles S; Johnston S; Khan S; Laffan J; Lane P; Leeman L; Lowe DM; Mahabir S; Lochlainn DJM; McDermott E; Misbah S; Moghaddas F; Morsi H; Murng S; Noorani S; O'Brien R; Patel S; Price A; Rahman T; Seneviratne S; Shrimpton A; Stroud C; Thomas M; Townsend K; Vaitla P; Verma N; Williams A; Burns SO; Savic S; Richter AG
    Clin Exp Immunol; 2022 Sep; 209(3):247-258. PubMed ID: 35641155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
    Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience.
    Shields AM; Burns SO; Savic S; Richter AG;
    J Allergy Clin Immunol; 2021 Mar; 147(3):870-875.e1. PubMed ID: 33338534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience.
    Shields AM; Tadros S; Al-Hakim A; Nell JM; Lin MMN; Chan M; Goddard S; Dempster J; Dziadzio M; Patel SY; Elkalifa S; Huissoon A; Duncan CJA; Herwadkar A; Khan S; Bethune C; Elcombe S; Thaventhiran J; Klenerman P; Lowe DM; Savic S; Burns SO; Richter AG
    Front Immunol; 2022; 13():984376. PubMed ID: 36211396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors.
    Mohamed KM; Guevara-Hoyer K; García CJ; Bravo LG; Jiménez-Huete A; de la Peña AR; Valeros BM; Velázquez CC; López EC; Cabello N; Estrada V; Corbí ÁL; Fernández-Arquero M; Ocaña A; Delgado-Iribarren A; Martínez-Novillo M; Bolaños E; Anguita E; Peña A; Benavente C; Benítez Fuentes JD; Pérez Segura P; Sánchez-Ramón S
    Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic or relapsing COVID-19 in immunodeficiency.
    Brown LK; Moran E; Goodman A; Baxendale H; Bermingham W; Buckland M; AbdulKhaliq I; Jarvis H; Hunter M; Karanam S; Patel A; Jenkins M; Robbins A; Khan S; Simpson T; Jolles S; Underwood J; Savic S; Richter A; Shields A; Brown M; Lowe DM
    J Allergy Clin Immunol; 2022 Feb; 149(2):557-561.e1. PubMed ID: 34780850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
    Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
    Front Immunol; 2022; 13():840126. PubMed ID: 35359967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
    Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
    Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.
    Lang-Meli J; Fuchs J; Mathé P; Ho HE; Kern L; Jaki L; Rusignuolo G; Mertins S; Somogyi V; Neumann-Haefelin C; Trinkmann F; Müller M; Thimme R; Umhau M; Quinti I; Wagner D; Panning M; Cunningham-Rundles C; Laubner K; Warnatz K
    J Clin Immunol; 2022 Feb; 42(2):253-265. PubMed ID: 34893946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serology-based therapeutic strategy in SARS-CoV-2-infected patients.
    Garcia-Muñoz R; Farfán-Quiroga G; Ruiz-de-Lobera N; Feliu J; Anton-Remirez J; Nájera Irazu MJ; Lisa Catón V; Oteo-Revuelta JA
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108214. PubMed ID: 34649116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
    Bronstein Y; Adler A; Katash H; Halutz O; Herishanu Y; Levytskyi K
    J Med Virol; 2022 Mar; 94(3):1241-1245. PubMed ID: 34755363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report.
    Nyström K; Hjorth M; Fust R; Nilsdotter-Augustinsson Å; Larsson M; Niward K; Nyström S
    BMC Infect Dis; 2022 Apr; 22(1):362. PubMed ID: 35410137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
    D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E;
    Front Immunol; 2022; 13():911339. PubMed ID: 35711444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
    Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
    Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of pregnant patients treated with REGEN-COV during the COVID-19 pandemic.
    Levey NH; Forrest AD; Spielman DW; Easley KA; Dude CM; Badell ML
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100673. PubMed ID: 35671984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection.
    Schuh AJ; Satheshkumar PS; Dietz S; Bull-Otterson L; Charles M; Edens C; Jones JM; Bajema KL; Clarke KEN; McDonald LC; Patel S; Cuffe K; Thornburg NJ; Schiffer J; Chun K; Bastidas M; Fernando M; Petropoulos CJ; Wrin T; Cai S; Adcock D; Sesok-Pizzini D; Letovsky S; Fry AM; Hall AJ; Gundlapalli AV
    Microbiol Spectr; 2022 Aug; 10(4):e0124722. PubMed ID: 35856710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.